MyFinsight
Home
Blog
About
Marketable securities
$759,650K
(104.72%↑ Y/Y)
Cash and cash
equivalents
$135,505K
(13.45%↑ Y/Y)
Prepaid expenses and
other current assets
$12,184K
(138.02%↑ Y/Y)
Total current assets
$907,339K
(83.07%↑ Y/Y)
Operating lease
right-of-use assets
$1,502K
(166.31%↑ Y/Y)
Other long-term
assets
$1,242K
(-82.84%↓ Y/Y)
Property and equipment,
net
$140K
(-69.70%↓ Y/Y)
Total assets
$910,223K
(80.64%↑ Y/Y)
Total liabilities and
stockholders' equity
$910,223K
(80.64%↑ Y/Y)
Total stockholders'
equity
$895,149K
(83.25%↑ Y/Y)
Total liabilities
$15,074K
(-2.21%↓ Y/Y)
Accumulated deficit
-$403,278K
(-35.62%↓ Y/Y)
Accumulated other
comprehensive (loss) income
-$1,905K
(-976.27%↓ Y/Y)
Additional paid-in capital
$1,300,259K
(65.44%↑ Y/Y)
Total current
liabilities
$14,161K
(-6.90%↓ Y/Y)
Long-term liabilities
$913K
(347.55%↑ Y/Y)
Common stock, par value
0.001 authorized...
$73K
(23.73%↑ Y/Y)
Accrued expenses and
other current...
$13,790K
(7.23%↑ Y/Y)
Accounts payable
$371K
(-84.22%↓ Y/Y)
Back
Back
Balance Sheet
Enliven Therapeutics, Inc. (ELVN)
Enliven Therapeutics, Inc. (ELVN)
source: myfinsight.com